EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.
- DOI
- 10.1016/j.gastrohep.2026.502871
- Published
- 2026 Oct 7
- Container
- Gastroenterologia y hepatologia
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.gastrohep.2026.502871,
title = {EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.},
author = {Muñoz JF and Gutiérrez-Casbas A and Rodríguez C and Gisbert JP and Riestra S and Herrera de Guise C and Vera-Mendoza I and Martínez-Montiel MP and Bernardo S and Medeiros I and Aparicio J and Tagarro I and Letosa Abián T and Montoto C and Casellas F},
year = {2026},
journal = {Gastroenterologia y hepatologia},
doi = {10.1016/j.gastrohep.2026.502871},
url = {https://doi.org/10.1016/j.gastrohep.2026.502871}
}RIS
TY - JOUR TI - EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease. AU - Muñoz JF AU - Gutiérrez-Casbas A AU - Rodríguez C AU - Gisbert JP AU - Riestra S AU - Herrera de Guise C AU - Vera-Mendoza I AU - Martínez-Montiel MP AU - Bernardo S AU - Medeiros I AU - Aparicio J AU - Tagarro I AU - Letosa Abián T AU - Montoto C AU - Casellas F PY - 2026 JO - Gastroenterologia y hepatologia DO - 10.1016/j.gastrohep.2026.502871 UR - https://doi.org/10.1016/j.gastrohep.2026.502871 ER -
APA
JF, M., A, G., C, R., JP, G., S, R., C, H. D. G., I, V., MP, M., S, B., I, M., J, A., I, T., T, L. A., C, M., & F, C. (2026). EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.. Gastroenterologia y hepatologia. https://doi.org/10.1016/j.gastrohep.2026.502871
Source records
- pubmed · retrieved 2026-11-10T15:04:04.935Z